Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
News | November 27, 2024
Recently we proudly hosted our first Capital Markets Day, welcoming around 50 investors and key stakeholders.
The program featured insights from our executive management team and external speakers, followed by a Q&A session and a unique opportunity to explore our state-of-the-art facilities. This event marked an important step in strengthening our dialogue with the financial community and sharing our vision, strategy, and future opportunities.
To ensure everyone has the chance to see the event, the recording is available here: https://ir.financialhearings.com/devyser-cmd-2024
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More